EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Andrographis paniculata or favipiravir in Mild COVID-19: A randomized control trial

Rujipas Sirijatuphat, Navin Horthongkham, Chutikarn Chaimayo, Patimaporn Wongprompitak, Wuttikrai Kongsankum, Phornnapa Charoenkij, Titchaphorn Palo, Suthatip Mahajaroensiri, Nalinthika Nathananwanit, Sansanee Senawong, Wannee Kantakamalakul, Pravit Akarasereenont und 1 weitere

Phytomedicine Plus · 2025-08 · 5 (3) · 100858

DOI: 10.1016/j.phyplu.2025.100858 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine Plus, 2025-08. Verfasst von Rujipas Sirijatuphat und 12 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Mahidol University Faculty of Medicine Siriraj Hospital.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The COVID-19 pandemic led to an urgent search for effective treatments. Andrographis paniculata (AP), a traditional herbal medicine, has shown potential due to its antiviral and anti-inflammatory properties. This study aimed to compare the efficacy and safety of AP capsules with favipiravir (FV) in treating mild COVID-19 patients.

Methods

This randomized, double-blind trial was conducted at Siriraj Hospital, Thailand. This study was in the Thai Clinical Trials Registry register, which number is TCTR20240802007. The study included patients aged 18–59 who were diagnosed with mild COVID-19. Participants were randomly assigned to receive either AP capsules (180 mg/day) or FV for five days, with a 10-day follow-up period. Primary outcomes included changes in viral load, pneumonia incidence, and symptom improvement. Secondary outcomes focused on viral clearance and adverse events.

Results

A total of 190 participants (95 per group) were enrolled. By day 10, none had developed pneumonia. Both AP and FV effectively reduced viral load, with the Mann-Whitney U-test showing statistical significance (p < 0.05). The AP group showed greater improvement in specific symptoms, particularly in phlegm (1.15 ± 1.58 vs. 1.9 ± 2.04, p = 0.004) and headache (0.15 ± 0.51 vs. 0.47 ± 1.25, p = 0.033), compared to the FV group. Adverse events were minimal and similar between the two groups.

Conclusion

Both AP and FV effectively reduced symptoms and viral load with minimal side effects. However, AP showed superior improvements in phlegm and headaches. Consequently, physicians may regard AP as an appropriate option for COVID-19 patients to alleviate symptoms.

Förderung

  • Mahidol University Faculty of Medicine Siriraj Hospital

Zitieren

APA

Sirijatuphat, R., Horthongkham, N., Chaimayo, C., Wongprompitak, P., Kongsankum, W., Charoenkij, P., Palo, T., Mahajaroensiri, S., Nathananwanit, N., Senawong, S., Kantakamalakul, W., Akarasereenont, P., & Permpikul, C. (2025). Andrographis paniculata or favipiravir in Mild COVID-19: A randomized control trial. Phytomedicine Plus, 5(3), 100858. https://doi.org/10.1016/j.phyplu.2025.100858

Vancouver

Sirijatuphat R, Horthongkham N, Chaimayo C, Wongprompitak P, Kongsankum W, Charoenkij P, et al. Andrographis paniculata or favipiravir in Mild COVID-19: A randomized control trial. Phytomedicine Plus. 2025;5(3):100858. doi:10.1016/j.phyplu.2025.100858

BibTeX
@article{Sirijatuphat2025,
  author = {Sirijatuphat, Rujipas and Horthongkham, Navin and Chaimayo, Chutikarn and Wongprompitak, Patimaporn and Kongsankum, Wuttikrai and Charoenkij, Phornnapa and Palo, Titchaphorn and Mahajaroensiri, Suthatip and Nathananwanit, Nalinthika and Senawong, Sansanee and Kantakamalakul, Wannee and Akarasereenont, Pravit and Permpikul, Chairat},
  title = {Andrographis paniculata or favipiravir in Mild COVID-19: A randomized control trial},
  journal = {Phytomedicine Plus},
  year = {2025},
  volume = {5},
  number = {3},
  pages = {100858},
  doi = {10.1016/j.phyplu.2025.100858}
}
Kostenlos starten →